Mekophar Chemical Pharmaceutical Joint Stock Company
UUPCOM:MKP25,600.00
VND
+500.00
(+1.99%)
ISIN
VN000000MKP6
Return %
Stock
S&P 500
1Y
-5.19
14.20
3Y
-4.48
81.12
5Y
-47.76
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Lan Thi Huynh
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ho Chi Minh City Vietnam
- IPO Date
- Jan 29, 2018
- Website
- mekophar.com
- Similar Companies
- Business
- Mekophar Chemical Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical and biotechnology company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical formulations, active pharmaceutical ingredients, biological products, medical devices, cosmetics, and dietary supplements, as well as the provision of stem cell banking and regenerative medicine services. The company operates through distinct business segments comprising Pharmaceutical Manufacturing, Commercial Trading and Distribution, and Biotechnology and Stem Cell Services. Its extensive pharmaceutical portfolio encompasses multiple therapeutic categories and dosage formats, including antibiotics, such as beta-lactam, cephalosporin, and non-beta-lactam anti-infectives; cardiovascular and metabolic agents; gastrointestinal medications; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs; respiratory and antihistamine treatments; central nervous system therapies; vitamins, minerals, and functional health supplements; and dermatological and topical preparations. The company manufactures products across diverse delivery systems, such as compressed tablets, film-coated tablets, effervescent tablets, hard capsules, soft gelatin capsules, powders and granules for oral suspension, liquid syrups, topical creams and ointments, and sterile injectable ampoules and vials. Through its specialized biotechnology division, the Mekostem Stem Cell Bank, the company provides comprehensive biomedical services, including umbilical cord blood processing, umbilical cord tissue isolation, mesenchymal and epithelial stem cell cryopreservation, biological sample banking, and translational research for cell-based therapies. Mekophar also engages in the import, trading, and distribution of pharmaceutical raw materials, fine chemicals, diagnostic tools, and medical consumables. The company distributes its products domestically across Vietnam to hospitals, clinics, healthcare centers, wholesale distributors, and retail pharmacy chains, while exporting select generic drug lines to international markets across Southeast Asia, Africa, and other emerging regions. In recent operational developments, Mekophar has advanced the commercial operationalization and manufacturing capacity of its high-tech pharmaceutical production facility situated in the Saigon Hi-Tech Park in Ho Chi Minh City, engineered to align with European Union Good Manufacturing Practice and Japan Good Manufacturing Practice standards for non-beta-lactam oral solids and sterile injectable medications. In addition, the company has expanded strategic research collaborations and clinical partnerships with domestic medical universities, healthcare institutions, and international biotechnology entities to accelerate technology transfers, advance regenerative medicine protocols, and develop next-generation biopharmaceutical formulations. The company has also continued upgrading its manufacturing infrastructure, strengthening Good Storage Practice and Good Distribution Practice compliance across its logistics network, and introducing optimized value-added generic formulations to expand market share. Founded in 1975 and corporatized in 2001, Mekophar Chemical Pharmaceutical Joint Stock Company is headquartered in Ho Chi Minh City, Vietnam.